PortfoliosLab logoPortfoliosLab logo
CANC vs. CGON
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

CANC vs. CGON - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Tema Oncology ETF (CANC) and CG Oncology, Inc (CGON). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CANC achieves a 9.70% return, which is significantly lower than CGON's 59.56% return.


CANC

1D
2.41%
1M
-0.08%
YTD
9.70%
6M
7.59%
1Y
56.31%
3Y*
131.39%
5Y*
10Y*

CGON

1D
8.46%
1M
3.11%
YTD
59.56%
6M
65.29%
1Y
159.30%
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

CANC vs. CGON - Yearly Performance Comparison


2026 (YTD)20252024
CANC
Tema Oncology ETF
9.70%42.92%-3.59%
CGON
CG Oncology, Inc
59.56%44.77%-1.10%

Correlation

The correlation between CANC and CGON is 0.54, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.54

Correlation (All Time)
Calculated using the full available price history since Jan 25, 2024

0.53

The correlation between CANC and CGON has been stable across timeframes, ranging from 0.53 to 0.54 - a consistent structural relationship.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CANC vs. CGON — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CANC
CANC Risk / Return Rank: 8282
Overall Rank
CANC Sharpe Ratio Rank: 8181
Sharpe Ratio Rank
CANC Sortino Ratio Rank: 8383
Sortino Ratio Rank
CANC Omega Ratio Rank: 7070
Omega Ratio Rank
CANC Calmar Ratio Rank: 9292
Calmar Ratio Rank
CANC Martin Ratio Rank: 8484
Martin Ratio Rank

CGON
CGON Risk / Return Rank: 9393
Overall Rank
CGON Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
CGON Sortino Ratio Rank: 9393
Sortino Ratio Rank
CGON Omega Ratio Rank: 9090
Omega Ratio Rank
CGON Calmar Ratio Rank: 9494
Calmar Ratio Rank
CGON Martin Ratio Rank: 9595
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CANC vs. CGON - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Tema Oncology ETF (CANC) and CG Oncology, Inc (CGON). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CANCCGONDifference
Sharpe ratioReturn per unit of total volatility

-0.29

Sortino ratioReturn per unit of downside risk

-0.14

Omega ratioGain probability vs. loss probability

1.40

1.42

-0.02

Calmar ratioReturn relative to maximum drawdown

6.08

5.85

+0.24

Martin ratioReturn relative to average drawdown

16.57

18.07

-1.50

CANC vs. CGON - Sharpe Ratio Comparison

The current CANC Sharpe Ratio is 2.50, which is comparable to the CGON Sharpe Ratio of 2.79. The chart below compares the historical Sharpe Ratios of CANC and CGON, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CANC vs. CGON - Drawdown Comparison

The maximum CANC drawdown since its inception was -97.53%, which is greater than CGON's maximum drawdown of -67.47%. Use the drawdown chart below to compare losses from any high point for CANC and CGON.


Loading charts...

Drawdown Indicators


CANCCGONDifference

Max Drawdown

Largest peak-to-trough decline

-97.53%

-67.47%

-30.06%

Max Drawdown (1Y)

Largest decline over 1 year

-9.30%

-27.41%

+18.11%

Max Drawdown (3Y)

Largest decline over 3 years

-30.27%

Current Drawdown

Current decline from peak

-54.53%

-10.47%

-44.06%

Average Drawdown

Average peak-to-trough decline

-72.96%

-25.80%

-47.16%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.41%

8.85%

-5.44%

Volatility

CANC vs. CGON - Volatility Comparison

The current volatility for Tema Oncology ETF (CANC) is 6.51%, while CG Oncology, Inc (CGON) has a volatility of 16.31%. This indicates that CANC experiences smaller price fluctuations and is considered to be less risky than CGON based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CANCCGONDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.51%

16.31%

-9.80%

Volatility (6M)

Calculated over the trailing 6-month period

16.87%

42.03%

-25.16%

Volatility (1Y)

Calculated over the trailing 1-year period

22.72%

57.66%

-34.94%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

278.76%

66.53%

+212.23%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

278.76%

66.53%

+212.23%

Dividends

CANC vs. CGON - Dividend Comparison

CANC's dividend yield for the trailing twelve months is around 0.05%, while CGON has not paid dividends to shareholders.


PositionTTM202520242023
CANC
Tema Oncology ETF
0.05%0.06%3.00%0.56%
CGON
CG Oncology, Inc
0.00%0.00%0.00%0.00%

Frequently Asked Questions


CANC and CGON have a correlation of 0.54, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CGON has higher volatility (16.31%) compared to CANC (6.51%). In terms of maximum drawdown, CANC dropped -97.53% vs CGON's -67.47%.

CGON currently has the higher Sharpe Ratio (2.79 vs 2.50), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CANC and CGON

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer